Login to Your Account



Tails going up as immunotherapy treatment matures

By Anette Breindl
Senior Science Editor

Monday, April 18, 2016

NEW ORLEANS – At the annual meeting of the American Association for Cancer Research (AACR), data from several new studies showed progress toward the wish of their developers, as expressed by Yervoy (ipilimumab, Bristol Myers Squibb Co.) developer James Allison at the 2012 annual meeting: "Get that tail up."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription